Cargando…

1489. Safety and Performance of a Pharmacist-Driven Nasal MRSA PCR Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia at an Academic Medical Center

BACKGROUND: Limited published data supports the de-escalation of empiric anti-methicillin resistant Staphylococcus aureus (MRSA) antibiotics for suspected pneumonia upon negative nasal MRSA screening. Besides limited sample sizes, special populations, such as those who are immunocompromised and/or c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Lina, Pourali, Samaneh, Hitchcock, Matthew M, Ha, David R, Mui, Emily, Alegria, William, Diep, Calvin, Banaei, Niaz, Chang, Amy, Deresinski, Stan, Holubar, Marisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777533/ http://dx.doi.org/10.1093/ofid/ofaa439.1670

Ejemplares similares

Discontinuation Patterns and Cost Avoidance of a Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus Nasal Polymerase Chain Reaction Testing Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia
por: Meng, L, et al.
Publicado: (2021)

Effect of rapid methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction screening on vancomycin use in the intensive care unit
por: Diep, Calvin, et al.
Publicado: (2021)

Pharmacist-Driven MRSA Nasal PCR Screening and the Duration of Empirical Vancomycin Therapy for Suspected MRSA Respiratory Tract Infections
por: Woolever, Nathan L., et al.
Publicado: (2020)

Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
por: Fox, Emily, et al.
Publicado: (2022)

PCR Cycle-Threshold-Derived Toxin Identifies Patients at Low-Risk for Complications of C. difficile Infection Who Do Not Require Treatment
por: Hitchcock, Matthew, et al.
Publicado: (2017)

1092. Tuning Down Clostridioides difficile PCR Sensitivity Reduces Treatment for C. difficile Infection in Toxin-Negative Patients With No Increase in Adverse Outcomes
por: Hitchcock, Matthew, et al.
Publicado: (2018)

Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients
por: Lu, Brian, et al.
Publicado: (2023)

59. Impact of Pharmacist-Led De-Escalation of MRSA Therapy Using MRSA Nasal PCR
por: Salvatus, Marc, et al.
Publicado: (2021)

Elimination of Aerosol Ribavirin Use in Immunocompromised Patients with Metapneumovirus and Parainfluenza Virus Infections
por: Mui, Emily, et al.
Publicado: (2017)

824. Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience
por: Lu, Brian, et al.
Publicado: (2023)

Microbiologic Diagnosis of Lung Infection
por: Banaei, Niaz, et al.
Publicado: (2016)

210. Step-down from IV to oral therapy in patients with bacteremia due to Enterobacteriaceae: fluoroquinolones (FQ) vs. ß-lactams (BL) or trimethoprim-sulfamethoxazole (TMP-SMX)
por: Meng, Lina, et al.
Publicado: (2019)

Vancomycin resistance among MRSA
por: Kumar, V. Anil
Publicado: (2012)

Use of nares swab to de-escalate vancomycin for patients with suspected methicillin-resistant Staphylococcus aureus
por: Gentges, Joshua, et al.
Publicado: (2023)

227. Evaluation of Empiric Vancomycin Utilization at 72 Hours Post Admission: is De-escalation of Vancomycin Appropriate?
por: Naderi, Mandana, et al.
Publicado: (2020)

2532. Identifying Educational Needs and Improving Provider Knowledge Regarding the Management of Febrile Neutropenia
por: Chang, Amy, et al.
Publicado: (2019)

1489. Trends in Antimicrobial Resistance in N. gonorrhoeae Isolated in Korea During 2015–2017
por: Liu, Changseung, et al.
Publicado: (2018)

Effects of Pharmacist Intervention on the Utilization of Vancomycin in a Teaching Hospital
por: Tavakoli-Ardakani, Maria, et al.
Publicado: (2015)

Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis
por: Punjabi, Chitra, et al.
Publicado: (2019)

2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation
por: Demirhan, Salih, et al.
Publicado: (2023)

Takotsubo as Initial Manifestation of Non-Myopathic Cardiomyopathy Due to the Titin Variant c.1489G > T
por: Keller, Hans, et al.
Publicado: (2018)

79. Outcomes Associated with the Utilization of the Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Polymerase Chain Reaction (PCR) Assay to De-escalate Vancomycin Therapy in Patients with Suspected Pneumonia at a Rural Community Hospital
por: Tirupathi, Raghavendra, et al.
Publicado: (2020)

2010. A Significant Reduction in Empiric Vancomycin Days of Therapy for Suspected MRSA Pneumonia in Adult Non-ICU Patients After Implementation of a Rapid MRSA Nasal PCR Test with Antimicrobial Stewardship Intervention
por: Markoski, Nikola, et al.
Publicado: (2019)

Significance of bacterial and viral genotypes as a risk factor in driving cancer (Review)
por: Jangam, Diwash, et al.
Publicado: (2020)

1215. The Impact of MRSA Nasal PCR on Antibiotic De-escalation
por: Silverman, Adam, et al.
Publicado: (2023)

1266. Refining Antimicrobial Stewardship by De-escalating Vancomycin Using MRSA (Methicillin Resistant Staphylococcus aureus) Nasal Screening in a Community Hospital Setting
por: Shah, Ruta, et al.
Publicado: (2023)

1224. Outcomes of Empirical Vancomycin De-escalation Based on Methicillin-Resistant Staphylococcus aureus Nares
por: Xu, Jiachen, et al.
Publicado: (2023)

Resin-dentin bond stability of etch-and-rinse adhesive systems with different concentrations of MMP inhibitor GM1489
por: MIRANDA, Maria Elisa da Silva Nunes Gomes, et al.
Publicado: (2020)

1999. Does Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus PCR Nasal Screening Decrease Time to De-Escalation of MRSA Coverage in Patients with Pneumonia?
por: Waters, Dustin, et al.
Publicado: (2019)

Intermediate Vancomycin Susceptibility in a Community-associated MRSA Clone
por: Graber, Christopher J., et al.
Publicado: (2007)

Reduced vancomycin susceptibility in porcine ST9 MRSA isolates
por: Kwok, Gabriella M. L., et al.
Publicado: (2013)

Acute MRSA Sinusitis with Intracranial Extension and Marginal Vancomycin Susceptibility
por: Kumar, Parvathi S., et al.
Publicado: (2013)

Comparison of Empiric Antibiotic Escalation Therapy with Vancomycin (VAN) versus Linezolid (LIN) in Patients with Febrile Neutropenia
por: Mayer, Karin, et al.
Publicado: (2022)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

P1489: MANAGEMENT OF SICKLE CELL DISEASE WITH HYDROXYUREA: A SYSTEMATIC REVIEW FROM LOW- AND MIDDLE-INCOME COUNTRIES
por: Paintsil, V., et al.
Publicado: (2022)

Impact of a Pharmacist-driven Methicillin-resistant Staphylococcus aureus Polymerase Chain Reaction Nasal Swab Protocol on the De-escalation of Empiric Vancomycin in Patients with Pneumonia in a Rural Healthcare Setting
por: Dadzie, Precious, et al.
Publicado: (2019)

“Acute urinary antibiotics”—A simple metric to identify outpatient antibiotic stewardship opportunities in renal transplant
por: Zimmet, Alex, et al.
Publicado: (2023)

Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention
por: Benamu, Esther, et al.
Publicado: (2018)

Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections
por: Neoh, Hui-min, et al.
Publicado: (2007)

Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA
por: Bhise, Ketki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ku3el0hnf4hagmcuhj298emqvs